Literature DB >> 7073266

Pharmacokinetics of intramuscular ceforanide in infants, children, and adolescents.

A S Dajani, M C Thirumoorthi, R E Bawdon, J A Buckley, M Pfeffer, D R Van Harken, R D Smyth.   

Abstract

We studied the pharmacokinetics of intramuscular ceforanide in 46 infants, children, and adolescents, ranging in age from 1 month to 17 years. After the subjects were given 20-mg doses of ceforanide per kg, the mean peak plasma concentration was 56.3 microgram/ml (range, 27.0 to 95.0), the mean 8-h level was 5.9 microgram/ml (range, 1.5 to 13.5), and the mean 12-h level was 1.5 microgram/ml (range, 0.2 to 4.2). Ceforanide half-life varied with the ages of the patients: in 1- to 2-year-old children, in half-life was significantly shorter (1.5 h) than in younger or older children. Plasma concentrations at 8 and 12 h after a dose were lowest in 1- to 2-year-old children. There was no relationship between the area under the curve, the volume of distribution, or the body clearance of ceforanide to the ages of the patients. Within 6 h of administration of the drug, a mean of 77.5% of a dose was excreted in urine, and at the end of 12 h, virtually all (93.9%) of the administered dose was recovered in urine samples. The administration of ceforanide every 12 h did not result in drug accumulation. A dose of 20 mg of ceforanide per kg every 12 h is recommended for most pediatric patients. Dosage recommendations for 1- to 2 year-old children are presented.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7073266      PMCID: PMC181874          DOI: 10.1128/AAC.21.2.282

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  8 in total

Review 1.  Pediatric clinical pharmacology and the "therapeutic orphan".

Authors:  A K Done; S N Cohen; L Strebel
Journal:  Annu Rev Pharmacol Toxicol       Date:  1977       Impact factor: 13.820

2.  Clinical pharmacokinetics and safety of high doses of ceforanide (BL-S786R) and cefazolin.

Authors:  R D Smyth; M Pfeffer; A Glick; D R Van Harken; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

3.  Clinical pharmacokinetics in infants and children.

Authors:  A Rane; J T Wilson
Journal:  Clin Pharmacokinet       Date:  1976       Impact factor: 6.447

4.  Human pharmacokinetics of a new braod-spectrum parenteral cephalosporin antibiotic, ceforanide.

Authors:  M Pfeffer; R C Gaver; D R Van Harken
Journal:  J Pharm Sci       Date:  1980-04       Impact factor: 3.534

5.  The 24-hour true endogenous creatinine clearance in infants and children without renal disease.

Authors:  J WINBERG
Journal:  Acta Paediatr       Date:  1959-09       Impact factor: 2.299

6.  Laboratory evaluation of BL-S786, a cephalosporin with broad-spectrum antibacterial activity.

Authors:  F Leitner; M Misiek; T A Pursiano; R E Buck; D R Chisholm; R G DeRegis; Y H Tsai; K E Price
Journal:  Antimicrob Agents Chemother       Date:  1976-09       Impact factor: 5.191

7.  Comparative pharmacokinetics of ceforanide (BL-S786R) and cefazolin in laboratory animals and humans.

Authors:  F H Lee; M Pfeffer; D R Van Harken; R D Smyth; G H Hottendorf
Journal:  Antimicrob Agents Chemother       Date:  1980-02       Impact factor: 5.191

8.  Failure of probenecid to alter the pharmacokinetics of ceforanide.

Authors:  J F Jovanovich; L D Saravolatz; K Burch; D J Pohlod
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

  8 in total
  4 in total

Review 1.  Ceforanide. A review of its antibacterial activity, pharmacokinetic properties and clinical efficacy.

Authors:  D M Campoli-Richards; T E Lackner; J P Monk
Journal:  Drugs       Date:  1987-10       Impact factor: 9.546

2.  In Silico Dose Prediction for Long-Acting Rilpivirine and Cabotegravir Administration to Children and Adolescents.

Authors:  Rajith K R Rajoli; David J Back; Steve Rannard; Caren Freel Meyers; Charles Flexner; Andrew Owen; Marco Siccardi
Journal:  Clin Pharmacokinet       Date:  2018-02       Impact factor: 6.447

3.  Twice-daily intramuscular ceforanide therapy of Staphylococcus aureus endocarditis in parenteral drug abusers.

Authors:  R L Greenman; S M Arcey; D A Gutterman; R M Zweig
Journal:  Antimicrob Agents Chemother       Date:  1984-01       Impact factor: 5.191

4.  Comparison of cefoperazone and cefoxitin concentrations in serum and pelvic tissue of abdominal hysterectomy patients.

Authors:  R E Bawdon; D L Hemsell; S P Guss
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.